Phase I Trial of huA33 Plus 5-Fluorouracil (5FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer
18 Years
N/A
Both
Colorectal Cancer
Trial Information
Phase I Trial of huA33 Plus 5-Fluorouracil (5FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer
Purpose of the Research Study:
huA33 is an antibody that reacts with the A33 antigen which is produced by colorectal
cancers. Prior studies have shown that application of the huA33 antibody may delay the
growth of tumor cells producing the respective antigen.
Oxaliplatin and 5-FU are cytotoxic agents which are considered as standard treatment in
metastatic colorectal cancer. Leucovorin is a vitamin which enhances the effect of 5FU.
The primary purpose of this study is to determine whether the combination huA33 plus
Oxaliplatin, 5-FU and Leucovorin is safe and what side effects occur.
Description of Research Procedures:
The first step is to determine whether or not patients are eligible for participation in the
study. Apart from general blood tests and x-ray studies needed, this involves testing with
regard to some special requirements:
- Three tests of stool to determine if it is positive for blood.
- Women of childbearing age must have a negative pregnancy test.
- If patients ever had a treatment with similar substances like huA33 before, a blood
sample needs to be tested for antibodies that may have developed against huA33.
After eligibility is established, huA33 will be administered intravenously over a period of
30 minutes once a week at a dose of 10 mg/m2. Every second week, Oxaliplatin, 5-FU and
Leucovorin are administered additionally. Oxaliplatin and Leucovorin will be given as an
infusion over 2 hours. Afterwards patients will receive an bolus infusion of 5-FU
intravenously followed by an infusion of 5-FU over 22 hours.
The doses of Oxaliplatin will be 85mg/m2, Leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus
infusion and 600mg/m2 as an continuous infusion. A complete treatment cycle consists of 12
weekly treatment days.
Patients will have an interview with their doctor and a physical examination before the
first day of treatment and before each therapy. Standard blood tests as well as special
blood tests to measure a possible reaction of the immune system to the huA33 antibody will
be done weekly before the treatment is started. The amount of blood to be drawn will be
20-30 ml during one cycle of the study.
X-rays and/or CT scans to measure the extend of the disease will be done at the start and on
week 12, which is considered to be the first day of the next cycle. Patients may continue
with this treatment until there is no evidence of tumor progression.
Inclusion Criteria:
Patients will be eligible for enrollment if they fulfill all of the following criteria:
1. Metastatic colorectal cancer
2. Histologically or cytologically proven colorectal cancer
3. Expected survival of at least 4 months.
4. Not more than 2 different pretreatment regimens
5. ECOG performance status 0-2.
6. Within the 2 weeks prior to the first dose of huA33, the following vital laboratory
parameters:
Lab Parameter Range
- Neutrophil count > 1.5 x 109/L
- Platelet count > 150 x 109/L
- Serum bilirubin < 2 mg/dL
- Creatinine clearance >50 ml/ min
7. Age ≥ 18 years
8. Able and willing to give valid written informed consent
Exclusion Criteria:
Patients will be excluded from the study for any of the following reasons:
1. Untreated active metastatic disease to the central nervous system defined as new or
enlarging lesions on CT or MRI.
2. Surgery or radiotherapy of brain metastases within 3 months prior to the first dose
of huA33.
3. Metastatic disease involving > 50% of liver volume.
4. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding
disorders.
5. Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first
dosing (6 weeks for nitrosoureas).
6. Previous treatment with Oxaliplatin.
7. Previous treatment with huA33 monoclonal antibody or antibody fragment.
8. Concomitant treatment with systemic corticosteroids. Topical or inhalational
corticosteroids are permitted.
9. Known HIV, Hepatitis B or C positivity.
10. Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.
11. Lack of availability of the patient for clinical and laboratory follow-up assessment.
12. Participation in any other clinical trial involving another investigational agent
within 4 weeks prior to first dosing.
13. Pregnancy or breastfeeding.
14. Women of childbearing potential: Refusal or inability to use effective means of
contraception.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the safety of the combination of huA33 and 5FU plus leucovorin and oxaliplatin in patients with metastatic colorectal cancer
Outcome Time Frame:
Duration of study
Safety Issue:
Yes
Principal Investigator
Christoph Renner, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Universitätsspital Zürich, Switzerland
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
LUD2003-005
NCT ID:
NCT00199797
Start Date:
October 2004
Completion Date:
July 2007
Related Keywords:
- Colorectal Cancer
- Colorectal Cancer
- huA33
- antibody
- chemotherapy
- Colorectal Neoplasms
Name | Location |
|---|
